tbuckley/cabot-search huggingface dataset:
THU0040 Impact of Baseline Conventional Disease Activity Variables, Imaging Assessment of RA Activity (Joint US and MRI Synovitis Scores), MMP-3 and Calprotectin Levels on Achievement of ACR70 Response in RA Patients after Etanercept Treatment: Table 1.
Authors: A. Pchelintseva, E. Panasyuk, N. Ionichenok, A. Zhornyak, A. Ilyina, I. Andrianova, M. Cherkasova, M. Severinova, A. Volkov, A. Smirnov, L. Denisov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Monitoring of RA activity is important in daily practice and clinical trials, in particular for subjects receiving biologics. As a result, new imaging tools and more objective biomarkers of synovial inflammation and joint destruction have been developed. <h3>Objectives</h3> To evaluate role of imaging methods (joint MRI, US), biomarkers (calprotectin-CP and MMP-3) and RA activity parameters in achievement of ACR70 response after Etanercept (ETN) therapy <h3>Methods</h3> 25 pts (mean age 49,4±13,7 yrs) with active RA despite stable doses of cDMARDs (DAS28 6,12±0,97) had received ETN 50 mg weekly sc for 24 weeks. RA duration was 6,38±5,9 yrs, 92% were women, 64%&gt;RF+. Clinical and laboratory evaluation was done at weeks 0 and 25. US exam was performed before start of ETN treatment and after 6 month of ETN therapy by the same independent sonographer. 7-joint score (grade 0–3) included wrist, intercarpal, 2–3 MCP, 2–3 PIP joints of the clinically dominant hand and knee was used. MRI was done at baseline and after end of ETN treatment. Assessment of 2–5 MCP joints of the clinically dominant hand (0-no synovitis, 1–10-severity of synovitis) was done by the same independent radiologist.CP and MMP-3 serum levels (ELISA) were measured at the same time points. Changes of all parameters since baseline were assessed. Predictive factors of achievement ACR70 responce were explored. <h3>Results</h3> All clinical, laboratory, MRI and US parameters of RA activity had significantly improved during ETN therapy (p&lt;0,05).We detected statistically significant difference only in baseline MRI synovitis score between responders and non-responders according ACR70 (p=0,0074). (table 1) We did not find any significant difference between groups in MeΔ at weeks 0–12 of ESR, CRP, CP and MMP-3, whereas MeΔ of SJC distinguished in ACR70 responders and non-responders (p=0,0494). <h3>Conclusions</h3> 1. US and MRI synovitis sum scores decreased significantly in parallel with CP and MMP-3 serum levels and RA activity variables during ETN therapy. 2. Low baseline MRI synovitis sum score is more useful in comparison with baseline US, CP, MMP-3 and conventional RA activity factors as predictive tool of good responce in RA during anti-TNF therapy. 3. Decrease of ESR, CRP, CP and MMP-3 at week 12 had not impact on ACR70 response at week 25. <h3>Disclosure of Interest</h3> None declared
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
Authors: Adel Samson, Matthew J Bentham, Karen Scott, Gerard Nuovo, Abigail Bloy, Elizabeth Appleton, Robert A Adair, Rajiv Dave, Adam Peckham-Cooper, Giles Toogood, Seishi Nagamori, Matthew Coffey, Richard Vile, Kevin Harrington, Peter Selby, Fiona Errington-Mais, Alan Melcher, Stephen Griffin
Journal: Gut (2016)

Objective Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular carcinoma (HCC). Furthermore, we extended this exemplar to other models of virus-associated cancer. Design and results Clinical grade oncolytic orthoreovirus (Reo) elicited innate immune activation within primary human liver tissue in the absence of cytotoxicity and independently of viral genome replication. As well as achieving therapy in preclinical models of HCC through the activation of innate degranulating immune cells, Reo-induced cytokine responses efficiently suppressed HCV replication both in vitro and in vivo. Furthermore, Reo-induced innate responses were also effective against models of HBV-associated HCC, as well as an alternative endogenous model of Epstein–Barr virus-associated lymphoma. Interestingly, Reo appeared superior to the majority of OVs in its ability to elicit innate inflammatory responses from primary liver tissue. Conclusions We propose that Reo and other select proinflammatory OV may be used in the treatment of multiple cancers associated with oncogenic virus infections, simultaneously reducing both virus-associated oncogenic drive and tumour burden. In the case of HCV-associated HCC (HCV-HCC), Reo should be considered as an alternative agent to supplement and support current HCV-HCC therapies, particularly in those countries where access to new HCV antiviral treatments may be limited.
Deferasirox (Exjade®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.
Authors: Elliott Vichinsky, Thomas Coates, Alexis A Thompson, Françoise Bernaudin, Martha Rodriguez, Lisa Rojkjaer, Matthew M Heeney
Journal: Blood (2008)
Systems Approaches to Cancer Biology
Authors: Tenley C. Archer, Elana J. Fertig, Sara J.C. Gosline, Marc Hafner, Shannon K. Hughes, Brian A. Joughin, Aaron S. Meyer, Stephen R. Piccolo, Ayesha N. Shajahan-Haq
Journal: Cancer Research (2016)

Cancer systems biology aims to understand cancer as an integrated system of genes, proteins, networks, and interactions rather than an entity of isolated molecular and cellular components. The inaugural Systems Approaches to Cancer Biology Conference, cosponsored by the Association of Early Career Cancer Systems Biologists and the National Cancer Institute of the NIH, focused on the interdisciplinary field of cancer systems biology and the challenging cancer questions that are best addressed through the combination of experimental and computational analyses. Attendees found that elucidating the many molecular features of cancer inevitably reveals new forms of complexity and concluded that ensuring the reproducibility and impact of cancer systems biology studies will require widespread method and data sharing and, ultimately, the translation of important findings to the clinic. Cancer Res; 76(23); 6774-7. ©2016 AACR.
THU0436 A Retrospective Non-Interventional Multi-Centre Study Evaluating Treatment Regimens Used in Psoriatic Arthritis Patients in Australia- The PSA Real Study
Authors: D. Nicholls, A. Nakayama, H. Griffiths, G. Littlejohn, P. Bird, L. Roberts, J. de Jager, J. Zochling, S. Richter, S. Louw, K. Tymms
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriatic arthritis (PsA) is a spondyloarthritis spectrum disease with prominent involvement of skin and joints. The management of PsA patients is often complex and there is no uniformity across the medical profession. The majority of PsA studies have been prospective clinical trials involving a homogenous and restricted patient population. This may not reflect real clinical practice where patients have co-morbidities and other clinical characteristics that preclude them from participating in clinical trials. <h3>Objectives</h3> To provide a cross sectional analysis of disease activity and management of PsA patients in the Australian population. <h3>Methods</h3> This was a retrospective non-interventional multi-centre study using the Audit4 clinical audit program, with de-identified and routinely collected clinical data sourced from participating rheumatology practices in the OPAL consortium (Optimising Patient outcomes in Australian rheumatoLogy) across Australia during November 2015<sup>1</sup>. Data collected included baseline characteristics, prevalence and duration of cDMARD and bDMARD treatments, DAS28-CRP results, and reasons for stopping therapy. <h3>Results</h3> A total of 3422 clinician diagnosed PsA patients were included in this study: 60% were female, mean age 54 years (±14) and mean disease duration 10 years (±9). Of patients with a valid treatment record (n=2948), 46% were on cDMARD monotherapy, 19% on bDMARD monotherapy, 13% on combination bDMARD and cDMARD therapy, 11% on combination cDMARD therapy and 10% were on no DMARDs. Of those with DAS28 CRP results (n=494), the highest mean DAS 28 CRP was 3.32 (±1.57) on combination cDMARD therapy, and the lowest DAS 28 CRP was 2.19 (±0.89) on bDMARD monotherapy. The most common reasons for cessation of cDMARD monotherapy was adverse reactions (41%), for bDMARD monotherapy lack of efficacy (26%) and combination bDMARD and cDMARD therapy either completed treatment or drug no longer required (37%). <h3>Conclusions</h3> Cross sectional analysis of this large cohort managed in rheumatology clinical practice suggests most are receiving DMARD therapies with less disease activity on bDMARD monotherapy. Adverse reactions and lack of efficacy remain common reasons for cessation of cDMARD and bDMARD monotherapy in PsA. <h3>References</h3> Tymms K, Littlejohn G. Optimising Patient Outcomes in Australian Rheumatology (OPAL): a clinician driven point of care observational data management consortium. Clin Exp Rheumatol 2014;32(85): S150-S152. <h3>Acknowledgement</h3> Celgene Pty Ltd. <h3>Disclosure of Interest</h3> None declared
PTH-141 Gastrointestinal Malignancy – Same Day CT Scanning Post Endoscopy Saves Time Resulting in Earlier MDT Decisions
Authors: HL Lee, S Peterson, AM Verma
Journal: Gut (2016)

<h3>Introduction</h3> Staging CT scanning is essential in guiding the management of patients with newly diagnosed gastrointestinal malignancy when discussed in multi-disciplinary team (MDT) meetings. Long waiting times for staging CT causes delays in MDT decision making for patients and initiating treatment. Kettering General Hospital (KGH) implemented a pathway in December 2014 in which patients with newly detected malignancy on endoscopy can have staging CT scan post endoscopy (same day). We are auditing the effectiveness of this pathway in terms of time saved. <h3>Methods</h3> Data was analysed between January 1<sup>st</sup> 2014 to December 31<sup>st</sup> 2015 from endoscopy, radiology and cancer MDT reporting systems to compare time from day of endoscopy to day of CT and to date of MDT discussion pre and post implementation of the pathway. Patients who underwent endoscopy in December 2014 were excluded, as the pathway was being implemented. <h3>Results</h3> There were 90 and 104 patients found to have new possible malignancy on endoscopy in 2014 and 2015 respectively. The median (and mean) days awaiting staging CT and MDT discussion prior to the pathway were 12.5 (11.4) days and 15.0 (16.0) days respectively. Since the implementation of the pathway, median (and mean) days for staging CT was 0 (1.6) days and MDT discussions were 6.0 (7.2) days (p = &lt;0.01). The median days saved waiting for a CT staging and MDT discussion are 12.5 and 9 days. <h3>Conclusion</h3> This data shows significant improvement in median time to MDT discussion from endoscopy since the pathway was implemented (15 vs 6 days). The patient pathway implemented by our organisation has helped shortened decision time for MDT outcomes and is highly effective in improving patient care. Patients are diagnosed and staged quickly, requiring fewer visits to the hospital and starting their treatment earlier. We commend this pathway to other endoscopy / radiology departments around the country. <h3>Disclosure of Interest</h3> None Declared
Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203.
Authors: David Straus, Ann LaCase, Malik Juweid, Lale Kostakogolu, Nathan Hall, Jeffery Johnson, Sin-Ho Jung, George Canellos, Lawrence Schwartz, Bruce Cheson
Journal: Blood (2007)
A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.
Authors: Fabiana Ostronoff, Megan Othus, Hagop M. Kantarjian, Soheil Meshinchi, Farhad Ravandi, Paul C. Hendrie, Stefan Faderl, Pamela S. Becker, Jorge E. Cortes, John M. Pagel, Stephen Petersdorf, John E. Godwin, Cheryl L Willman, Sherry A. Pierce, Alan F List, Ravinder K Sandhu, Roland B. Walter, Derek L. Stirewalt, Frederick R. Appelbaum, Elihu H. Estey
Journal: Blood (2012)
Multiple Myeloma: Clinical Implications of Cytogenetic Aberrations on Selected Plasma Cells on Conventional Cytogenetics and Interphase Flourescence In Situ Hibridization (FISH)
Authors: Rakesh Verma, Lalit Kumar, Ashutosh Halder, Atul Sharma, Ritu Gupta, Renu Saxena, Shyam S Chauhan, Subrata Sinha
Journal: Blood (2010)
Sarcopenia and Adipopenia Are Independent Prognostic Factors in Patients with Acute Myeloid Leukemia
Authors: Nobuhiko Nakamura, Yuhei Shibata, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Soranobu Ninomiya, Yasuhito Nannya, Masahito Shimizu, Takeshi Hara, Hisashi Tsurumi
Journal: Blood (2015)
Next-Generation Deep-Sequencing Enables a Quantitative Monitoring of RUNX1 Mutations in 534 Patients with Myelodysplastic/Myeloproliferative Neoplasms and Myelodysplastic Syndromes
Authors: Alexander Kohlmann, Vera Grossmann, Stefan Harbich, Frank Dicker, Niroshan Nadarajah, Tamara Alpermann, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2011)
Individualized Tumor Response Testing (ITRT) Profile Has a Prognostic Value in Childhood Acute Lymphoblastic Leukemia (ALL) and Acute Non-Lymphoblastic Leukemia (ANLL): The Multicenter Non-Interventional Long-Term Follow-up Study of Polish Pediatric Leukemia Study Group
Authors: Magdalena Piatkowska, Jan Styczynski, Beata Kolodziej, Beata Kurylo-Rafinska, Malgorzata Kubicka, Monika Pogorzala, Krzysztof Czyzewski, Robert Debski, Michal Matysiak, Iwona Malinowska, Elzbieta Stanczak, Walentyna Balwierz, Edyta Juraszewska, Jacek Wachowiak, Beningna Konatkowska, Maria Wieczorek, Igor Olejnik, Maryna Krawczuk-Rybak, Marta Kuzmicz, Jerzy Kowalczyk, Maria Jolanta Stefaniak, Wanda Badowska, Tomasz Szczepanski, Anna Balcerska, Lucyna Maciejka-Kapuscinska, Grazyna Sobol, Agnieszka Mizia-Malarz, Mariusz Wysocki
Journal: Blood (2011)
EphB4/ephrinB2 Interaction Mediate Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Spreading and Osteogenic Differentiation
Authors: Lin Li, Na Xu, Xuan Zhou, Jixian Huang, Yuling Li, Qisi Lu, Bolin He, Chengyun Pan, Qifa Liu, Liu Xiaoli
Journal: Blood (2015)
Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial
Authors: Jie Yu, Xiao-ling Yu, Zhi-yu Han, Zhi-gang Cheng, Fang-yi Liu, Hong-yan Zhai, Meng-juan Mu, Yan-mei Liu, Ping Liang
Journal: Gut (2016)

We read with interest the article by Bruix et al 1 on currently available treatment options for hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) is now the first-line technique for HCC ablation. RFA produces tumour necrosis in situ through temperature modification. Compared with RFA, microwave ablation (MWA) is one relatively recent advancement of thermoablative technology, which shows multiple theoretical advantages over RFA.2–4 We wish to report the results of a phase III randomised controlled trial (RCT) by comparing ultrasound-guided percutaneous cooled-probe MWA and RFA in ≤5 cm HCC (NCT 02539212).

From October 2008 to June 2015, 203 (265 nodules) subjects were randomised to MWA and 200 (251 nodules) were randomised to RFA. The indications were as follows: tumour size ≤5 cm in diameter, tumour number ≤3, Child–Pugh class A or B classification, no evidence of extrahepatic metastasis, vein or bile duct tumour embolus, lesions visible on ultrasound with an acceptable puncture path, an Eastern Cooperative Oncology Group performance status of 0–1, and no any other anticancer treatment previously. All the patients were percutaneously treated by a …
Rituximab Prophylaxis of EBV Reactivation after Unrelated Donor Transplants Using Anti-Thymocyte Globulin in the Conditioning Regimen.
Authors: Andrea Bacigalupo, Alida Dominietto, Monica Soracco, Sarah Pozzi, Anna Maria Raiola, Maria Teresa van Lint, Teresa Lamparelli, Adalberto Ibatici, Francesco Frassoni, Elisabetta Tedone
Journal: Blood (2005)
Effect of KGF (Palifermin) On Immune Reconstitution After Autologous Transplantation for Multiple Myeloma.
Authors: Emmanuel Clave, Corinne Douay, Claire Rabian, Maryvonnick Carmagnat, Helene Moins, Caroline Bompoint, Norbert C Gorin, Dominique Charron, Antoine Toubert, Laurent Garderet
Journal: Blood (2009)
PTH-010 Outcomes After Use of Patency Capsules Prior to Video Capsule Endoscopy
Authors: A Bond, P Collins
Journal: Gut (2016)

<h3>Introduction</h3> Capsule retention is an important complication in patients attending for video capsule endoscopy (VCE). It may necessitate endoscopic, surgical or medical intervention. Successful passage of a Patency capsule (PC) predicts the safe passage of the video capsule in the majority of patients with a high risk of stricturing disease. The PC disintegrates after 30 h exposure to GI secretions. It contains a radiofrequency tag that can be detected by a hand-held scanner. Its position in the gastrointestinal tract may be misinterpreted if plain abdominal X-ray is used to assess the position of the PC. Its position can be reliably detected by a limited, targeted CT scan. This strategy has been associated with a requirement for targeted CT scan in 46% of patients attending for PC.<sup>1</sup> <h3>Methods</h3> This was a retrospective observational study performed in a tertiary referral centre. Data was collected on all patients undergoing patency capsule from July 2013 to October 2015, at the Royal Liverpool University Hospital. Patients attended the hospital 30 hours after ingestion of the PC. Patients with a PC detected by hand-held scanner underwent a targeted, limited CT scan to identify the position of the capsule. Patients were referred for VCE if the PC had passed into the colon. <h3>Results</h3> 101 patients underwent investigation with PC. The commonest indication for a patency capsule test was known or suspected IBD in 22/101 and 54/101 patients, respectively. 55 / 101 patients required a low dose CT scan to identify the site of PC within the GI tract. 10 of 101 patients failed to achieve passage of the PC (9.9%). 9/10 patients had suspected or known small bowel Crohn’s disease. 4/9 patients had undergone prior small bowel imaging. (3 MR small bowel examinations and one barium study.) One MR scan had suggested a possible short stricture, but with no pre-stenotic dilatation to suggest functional obstruction. Of the remaining 91 patients, 76 had VCE examination. In 8 (10.5%) examinations, the capsule failed to reach the caecum within the recording period. In all 8, the capsule subsequently passed. 42 of the 76 VCE examinations were reported as normal. <h3>Conclusion</h3> 54% of patient attending PC required a targeted low dose CT scan to identify the site of the PC in the GI tract. Suspected or known small bowel Crohn’s disease is a risk for failure of the PC to leave the small bowel. Small bowel imaging does not reliably predict successful passage of the PC which correlates with previous reports indicating that normal small bowel imaging may not exclude lesions that cause retention of the video capsule. No capsule retentions were identified in patients with a successful patency test, supporting its use as a test in patients with clinical characteristics that increase concerns for capsule retention. <h3>Reference</h3> 1 Assadsangabi A, <i>et al</i>. <i>J Gastroenterol Hepatol</i>. 2015;<b>30</b>(6):984–9 <h3>Disclosure of Interest</h3> None Declared
MMP9, an important mediator of vascular remodelling, and risk of restenosis after percutaneous coronary intervention
Authors: PS Monraats, VD Sewgobind, FR de Vries, AH Zwinderman, MP de Maat, WR Agema, EP Slagboom, PA Doevendans, R de Winter, R Tio, J Waltenberger, RR Frants, A van der Laarse, E Vandewall, JW Jukema
Journal: Circulation (2005)
Manufacturers tell FDA why they should be able to promote drugs and devices off label
Authors: Jeanne Lenzer
Journal: BMJ (2016)

Manufacturers have told the US Food and Drug Administration (FDA) that restricting their ability to engage in “truthful and non-misleading speech” about off-label uses of drugs and devices infringes their rights to free speech.

The comments were made during hearings held in Washington, DC, on 9 and 10 of November on whether to allow manufacturers to promote drugs and medical devices for uses not approved by the FDA. Public comment on the proposal to loosen off-label promotion is open until 9 January 2017.

One in every five prescriptions in the US is estimated to be for off-label use. For example, the use of certain antibiotics in children, which have been tested and approved in adults, is one commonly accepted off-label use. But manufacturers are generally prohibited from promoting off-label use, with the exception of “safe harbor” activities, such as distributing reprints of peer reviewed journal articles …
Characterization of Two Patient Groups with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura, Defined by ADAMTS13 (n=195) and/or Classic Pentad (n=89).
Authors: Masanori Matsumoto, Ayami Isonishi, Seiji Kato, Hiromichi Ishizashi, Hideo Yagi, Yoshihiro Fujimura
Journal: Blood (2009)
AB0141 Depletion of Lymphoid-like Stromal Cells Impairs Tertiary Lymphoid Organ Formation in An Animal Model of Sjögren's Syndrome
Authors: J. Campos, S. Nayar, A.P. Croft, A.E. Denton, D.T. Fearon, C.D. Buckley, F. Barone
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tertiary lymphoid organs (TLO) characterised by germinal centre formation and B cell proliferation represent the histological hallmark of primary Sjögren9s syndrome (pSS). TLO persistence in the salivary glands is associated with systemic disease manifestations and lymphoma development in pSS patients (1). We previously demonstrated that gp38+ stromal cells are instrumental for TLO development and provide chemokines, such as CXCL13, CCL19 and CCL21 necessary for lymphocyte recruitment and organization (2). Similarly, in the lymph node, FAP+gp38+ lymphoid stromal cells regulate lymphocyte homing and homeostasis. Accordingly, deletion of FAP+gp38+ cells results in aberrant expression of lymphoid survival factors, disrupted lymph node organization and decreased ability to mount efficient immune responses (3, 4). <h3>Objectives</h3> To dissect the effects of FAP+gp38+ cell deletion in TLO dynamic and function in an animal model of pSS. <h3>Methods</h3> We used a model of conditional depletion of FAP-expressing cells, in which FAP-DTR mice were treated prophylactically with Diphtheria Toxin (DTx). Following depletion, submandibular salivary glands of FAP-DTR mice and littermate controls were intra-ductally cannulated with luciferase-encoding replication-deficient adenovirus to induce TLO formation and pSS-like disease as previously described (5). A combination of immunofluorescence, quantitative RT-PCR and flow cytometry on digested salivary glands was used to address the consequences of stromal cell deletion in the TLOs. <h3>Results</h3> We confirmed that in cannulated, inflamed wild-type salivary glands, FAP is upregulated on a population of activated stromal cells that expresses gp38 and produces lymphoid chemokines. As anticipated, analysis of DTx-treated FAP-DTR salivary glands reveals significantly decreased numbers of gp38+ stromal cells and deletion of FAP+ stromal cells leads to a significant defect in lymphoid chemokine production, decreased number of infiltrating lymphocytes and severely compromises TLO formation. <h3>Conclusions</h3> These data demonstrate that salivary glands gp38+ activated stromal cells express FAP and are required for TLO organization and maintenance in the tissue. Deletion of activated lymphoid stroma affects lymphocyte recruitment and organization, thus providing the rational for stromal cell targeting in TLO associated autoimmune diseases. <h3>References</h3> Theander et al. Ann Rheum Dis. 2011 Barone, Nayar et al. PNAS. 2015 Cremasco et al. Nat Immunol. 2014 Denton et al. PNAS. 2014 Bombardieri, Barone et al. JI. 2012 <h3>Disclosure of Interest</h3> None declared